Forbright, Inc. (VACH) compared with its closest peers (CABA, EDIT, OCGN, DNA, CMPX): P/E 136.5 vs industry 13.0. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Cabaletta Bio, Inc. (CABA) | $530.68M | -1.0 |
| Editas Medicine, Inc. (EDIT) | $476.10M | -1.1 |
| Ocugen, Inc. (OCGN) | $474.75M | — |
| Ginkgo Bioworks Holdings, Inc. (DNA) | $455.98M | -1.5 |
| Compass Therapeutics, Inc. (CMPX) | $431.31M | -12.8 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $399.98M | -5.3 |
| Fennec Pharmaceuticals Inc. (FENC) | $395.91M | 227.9 |
| X4 Pharmaceuticals, Inc. (XFOR) | $380.11M | -2.1 |
| Century Therapeutics, Inc. (IPSC) | $373.92M | -7.0 |
| Palisade Bio, Inc. (PALI) | $367.71M | -7.9 |
| Stock P/E | 136.5 |
| Sector P/E (Financials) | 15.1 |
| Industry P/E (Banking) | 13.0 |
| vs Sector | 803.8% |
| vs Industry | 952.1% |
VACH overview · VACH earnings · VACH financials · VACH KPIs · VACH investor relations · VACH ownership · VACH filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.